CMS granted broader coverage than it originally proposed for diagnostic laboratory tests using next generation sequencing, a breakthrough technology considered key to advancing personalized medicine that was approved following an unusual parallel review by CMS and FDA. CMS will not make labs study the diagnostics in return for covering them. The agency also expanded coverage to patients with relapsed, refractory or stage-three cancer and Medicare will pay for repeat testing when patients have new primary cancer diagnoses. FDA approved FoundationOne...